Interprotein Corporation - Product Pipeline Review - 2016

  • ID: 3665209
  • Company Profile
  • 33 pages
  • Global Markets Direct
1 of 4
Interprotein Corporation - Product Pipeline Review - 2016

Summary

‘Interprotein Corporation - Product Pipeline Review - 2016’, provides an overview of the Interprotein Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Interprotein Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Interprotein Corporation
- The report provides overview of Interprotein Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Interprotein Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Interprotein Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Interprotein Corporation’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Interprotein Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interprotein Corporation’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Interprotein Corporation Snapshot

Interprotein Corporation Overview

Key Information

Key Facts

Interprotein Corporation - Research and Development Overview

Key Therapeutic Areas

Interprotein Corporation - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Interprotein Corporation - Pipeline Products Glance

Interprotein Corporation - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Interprotein Corporation - Drug Profiles

IPC-003

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit VEGF for Solid Tumors

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit gp130 for Inflammation and Oncology

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit IgE for Allergies

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit RUNX1 for Acute Myeloid Leukemia

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptide to Inhibit gp130 for Inflammation and Oncology

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptides to Antagonize KIR for Oncology

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptides to Antagonize NKG2A for Oncology

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptides to Inhibit TIM-3 for Oncology

Product Description

Mechanism of Action

R&D Progress

Interprotein Corporation - Pipeline Analysis

Interprotein Corporation - Pipeline Products by Target

Interprotein Corporation - Pipeline Products by Route of Administration

Interprotein Corporation - Pipeline Products by Molecule Type

Interprotein Corporation - Pipeline Products by Mechanism of Action

Interprotein Corporation - Recent Pipeline Updates

Interprotein Corporation - Dormant Projects

Interprotein Corporation - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Interprotein Corporation, Key Information

Interprotein Corporation, Key Facts

Interprotein Corporation - Pipeline by Indication, 2016

Interprotein Corporation - Pipeline by Stage of Development, 2016

Interprotein Corporation - Monotherapy Products in Pipeline, 2016

Interprotein Corporation - Partnered Products in Pipeline, 2016

Interprotein Corporation - Partnered Products/ Combination Treatment Modalities, 2016

Interprotein Corporation - Out-Licensed Products in Pipeline, 2016

Interprotein Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016

Interprotein Corporation - Preclinical, 2016

Interprotein Corporation - Discovery, 2016

Interprotein Corporation - Pipeline by Target, 2016

Interprotein Corporation - Pipeline by Route of Administration, 2016

Interprotein Corporation - Pipeline by Molecule Type, 2016

Interprotein Corporation - Pipeline Products by Mechanism of Action, 2016

Interprotein Corporation - Recent Pipeline Updates, 2016

Interprotein Corporation - Dormant Developmental Projects,2016

Interprotein Corporation, Other Locations

List of Figures

Interprotein Corporation - Pipeline by Indication, 2016

Interprotein Corporation - Pipeline by Stage of Development, 2016

Interprotein Corporation - Monotherapy Products in Pipeline, 2016

Interprotein Corporation - Pipeline by Target, 2016

Interprotein Corporation - Pipeline by Molecule Type, 2016

Interprotein Corporation - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll